key: cord-0730729-w2vevq02
authors: Williams, Lucy R; Ferguson, Neil M; Donnelly, Christl A; Grassly, Nicholas C
title: Measuring vaccine efficacy against infection and disease in clinical trials: sources and magnitude of bias in COVID-19 vaccine efficacy estimates
date: 2021-10-26
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab914
sha: 632effa788a273507b0b43fc5a1eea72bf3e0863
doc_id: 730729
cord_uid: w2vevq02

BACKGROUND: Phase III trials have estimated COVID-19 vaccine efficacy (VE) against symptomatic and asymptomatic infection. We explore the direction and magnitude of potential biases in these estimates and their implications for vaccine protection against infection and against disease in breakthrough infections. METHODS: We developed a mathematical model that accounts for natural and vaccine-induced immunity, changes in serostatus and imperfect sensitivity and specificity of tests for infection and antibodies. We estimated expected biases in VE against symptomatic, asymptomatic and any SARS͏CoV2 infections and against disease following infection for a range of vaccine characteristics and measurement approaches, and the likely overall biases for published trial results that included asymptomatic infections. RESULTS: VE against asymptomatic infection measured by PCR or serology is expected to be low or negative for vaccines that prevent disease but not infection. VE against any infection is overestimated when asymptomatic infections are less likely to be detected than symptomatic infections and the vaccine protects against symptom development. A competing bias towards underestimation arises for estimates based on tests with imperfect specificity, especially when testing is performed frequently. Our model indicates considerable uncertainty in Oxford-AstraZeneca ChAdOx1 and Janssen Ad26.COV2.S VE against any infection, with slightly higher than published, bias-adjusted values of 59.0% (95% uncertainty interval [UI] 38.4 to 77.1) and 70.9% (95% UI 49.8 to 80.7) respectively. CONCLUSIONS: Multiple biases are likely to influence COVID-19 VE estimates, potentially explaining the observed difference between ChAdOx1 and Ad26.COV2.S vaccines. These biases should be considered when interpreting both efficacy and effectiveness study results.

The coronavirus disease phase III vaccine trials have demonstrated efficacy against symptomatic infection for multiple vaccines, with estimates ranging from 50% to 95% [1] . Yet a vaccine that protects against symptomatic disease may work by preventing infection, (infectionblocking vaccine), by preventing progression to symptoms upon infection (disease-blocking vaccine), or by a combination of these two mechanisms (Supplementary Figure 1) [2] . Understanding the extent to which the COVID-19 vaccines protect against infection is important because the success of their vaccination programmes is highly contingent not only on symptomatic cases, but also asymptomatic infection and community transmission [3] .

The predominant primary outcome of the COVID-19 vaccine trials is vaccine efficacy (VE) against the first case of PCR-confirmed symptomatic disease, . This is measured by PCR-testing trial participants with COVID-19 symptoms, and is sensitive to the clinical case definition [4] . As secondary outcomes, most trials also measure the incidence of asymptomatic infections, using either i) regular swabbing and PCR-testing, or ii) serological testing for anti-nucleocapsid antibodies at pre-specified time intervals, which allows seroconversion after infection to be identified for vaccines based on the spike protein (Table 1) . Both strategies allow for estimation of VE against asymptomatic infection ( ) and VE against any infection ( ).

is a complex outcome due to its relationship with the two mechanisms of VE. A vaccine that protects only against infection will reduce the number of symptomatic and asymptomatic infections in equal proportions, leading to a positive . Yet a vaccine that protects against symptom development will convert symptomatic cases to asymptomatic, potentially giving a negative .

The counterintuitive interpretation of this outcome has been noted [2, 5] , but the relationship between , and VE against progression to symptoms ( ) has not been quantified.

M a n u s c r i p t 6 Estimates of VE are known to be biased by factors such as imperfect test sensitivity and specificity and the accumulation of immunity over time [6] [7] [8] . However, there has been little discussion on the potential biases of the COVID-19 VE estimates [9, 10] . We developed a mathematical model of a vaccine trial to investigate the factors affecting observed values of VE. We first illustrate parameters affecting measured , then quantify the influence of different biases on VE estimates, notably the impact of i) the build-up of immunity from undetected asymptomatic infections, ii) imperfect test sensitivity and specificity for alternative testing strategies, iii) differential detection of asymptomatic and symptomatic infections, and iv) confounding of VE and probability of symptoms by age. We finish by estimating bias-adjusted VEs for two COVID-19 vaccines.

VE is defined as 1-RR where RR is some measure of the relative risk in the vaccine compared with the control arm [11] . For most primary and secondary outcomes of the COVID-19 vaccine trials, the relative risk is based on an incidence rate ratio (IRR) such that -⁄ -⁄ where and are the incidence rate in the vaccine and control groups respectively.

For outcomes measured at fixed time points (e.g., seroconversions), the relative risk can be calculated using the cumulative incidence ratio (CIR) such that ⁄ ⁄ where and are the cumulative incidence in the vaccine and control groups respectively. For a "l k " v VE based on cumulative incidence approximates that based on the incidence rate M a n u s c r i p t 7 for low incidence or short follow-up periods, but biases towards zero as follow-up time and incidence increase [8] .

For vaccines that protect against infection and/or symptoms, VE against symptomatic infection is given by (1) [12] . VE against asymptomatic infection depends on the incidence of asymptomatic infections that are not prevented by the vaccine and on symptomatic infections that the vaccine prevents from progressing, such that (2) where is the probability of symptoms in the absence of vaccination. Substituting equation (1) 

The model follows a susceptible, infected, recovered (SIR) structure, implemented as a Markov model, and allows for asymptomatic and symptomatic infections, natural immunity, changes in serostatus and imperfect test sensitivity and specificity. We assume a constant infection rate over

and their risk of then developing symptoms is reduced by . We assume no heterogeneity in population characteristics but perform a sensitivity analysis to assess the effect of variation in and VE by age.

We model two testing approaches for asymptomatic infections, i) weekly PCR testing and ii) serological testing at 1, 2, 6, 12 and 24 months after baseline. We assume that responsive PCR testing detects all symptomatic infections. Observed VE is calculated from the simulated incidence of detected infections in each trial arm. Efficacy is estimated as 1-IRR for all outcomes except those estimated using serology, for which efficacy is estimated as 1-CIR, using the cumulative number of Application to COVID-19

Applying the model to COVID-19, we assumed a natural probability of developing symptoms upon infection of 0.67 [13] , a serology test specificity of 99.84% [14] and sensitivity of 95% and 80% to symptomatic and asymptomatic infections, respectively [15] . We used data on the probability of PCR detection over time since infection for individuals without symptoms [16] to estimate the probability of detecting an asymptomatic infection with weekly PCR swabbing (Supplementary 

The build-up of immunity from undetected asymptomatic infections caused to bias in Imperfect test characteristics biased efficacy estimates towards zero. Factors increasing the magnitude of the bias were: reduced specificity, reduced sensitivity, increased testing frequency, and calculation with the CIR instead of the IRR. Although the serology estimated was based on the CIR (as person-time at risk is unknown), the bias was usually lower than the weekly-PCR M a n u s c r i p t 11 estimate, for a given sensitivity and specificity, due to the lower frequency of testing ( Figure 3 ). This led to substantial bias particularly in low incidence settings. For example, with a high specificity (99.8%) and sensitivity (100%), a true of 70% in a low incidence setting (5% per year) was underestimated at 23%.

For a vaccine that was protective against symptom development ( > 0), was overestimated when asymptomatic infections were less likely to be detected than symptomatic infections ( Figure 4 ). The greater the difference in the detection probabilities and the greater the v ' r the greater the overestimation.

These results were insensitive to adding age stratification to the probability of symptoms. However, also adding age-stratification to VE led to biased and estimates, when not adjusted for age ( Figure 5 ). When VE decreased with age and the probability of symptoms increased, was overestimated and underestimated, while the opposite was observed when efficacy increased with age. The magnitude of the difference was greater with an increased association between age and the probability of symptoms, and between age and efficacy.

Estimating VEin, VEpr, and the likely bias from the published trial results

Applying Equations 3 and 4 to the reported trial results gave an estimated for ChAdOx1 of 43.6% (95% CI 20.6-59.9) ( 

Accurately estimating COVID-19 VE outcomes is important to understand vaccine benefits, their likely impact on transmission and the long-term prospects for disease control. Simulating a COVID-19

vaccine trial helps to characterise the likely influence of biases and may help to explain differences seen between vaccines, trials, and populations.

We firstly derived the relationship between with efficacy against infection and against We explain these overall expected differences by four likely biases acting in the COVID-19 trials. 2) Imperfect test sensitivity and specificity bias estimates towards zero, with greater bias with higher frequency of testing, lower infection rate and for VE based on cumulative incidence rather than incidence rates. This bias is caused by false positives in both trial arms, and is greater with higher ratios of false positives to true positives [6] . It has potential to affect all VE outcomes but is likely to affect estimates of and more than , because the combined probability A c c e p t e d M a n u s c r i p t 14

asymptomatic is unaltered by the vaccine. Therefore, the rate at which immunity from asymptomatic infections accumulates, relative to the detection of symptomatic infections, is equivalent across trial arms, leading to an underestimation of [8, 33 ]. Yet for disease-blocking vaccines, a greater proportion of infections in the vaccine arm will be asymptomatic, accelerating the acquisition of immunity from undetected infections and introducing a conflicting upward bias.

Our model and real-world effectiveness studies suggest the COVID-19 vaccines protect against both infection and symptoms [34, 35] . Therefore we expect the overall direction of this bias to be towards zero, and for its magnitude to be greater for vaccines with higher .

adjusted for age. This is due to older participants contributing more to estimates than younger participants, who contribute more to estimates. This bias is dependent on the probability of symptoms increasing with age, for which there is mixed evidence [37] [38] [39] . However, it should be considered when interpreting estimates based on different subgroups, such as estimates based on a subgroup with serological data when is based on the total population.

These biases also apply to effectiveness studies, based on cohort or case-control designs. Notably, the bias arising from differential detection of asymptomatic and symptomatic infections will likely be greater in real-world studies, where asymptomatic testing is less rigorous. This should be considered when comparing real-world and trial reported estimates, as it could lead to greater bias towards overestimation of in effectiveness studies.

Limitations to our analysis include uncertainties over parameter estimates. There is limited evidence on serology and PCR test sensitivities for asymptomatic infections, and how these change over time.

As we show, differences in test sensitivity by symptom status can lead to overestimation of , so A c c e p t e d M a n u s c r i p t 15 further studies are needed to clarify the potential role of this bias. We also did not consider the v ' ff v r l l h w h l r v r l l r l cal test sensitivity. Multiple COVID-19 vaccines reduce SARS-CoV-2 viral load [18, 40] , and lower load infections are less likely to lead to seroconversion [41] . Therefore serology-based efficacy estimates may be more representative of high viral load infections than all infections, and may be comparable to estimates based on DNA sequenced swabs, which must exceed a threshold viral load to be sequenced. Finally, we do not consider point prevalence estimates from single time point PCR swabs, however this has been explored elsewhere [9, 10] .

In conclusion, multiple biases have the potential to influence COVID-19 VE estimates, with their direction and magnitude dependent on the vaccine properties and testing strategies. These biases may explain differences between the ChAdOx1 and Ad26.COV2.S trial estimates despite similar vaccine platform technologies, and should be considered when interpreting efficacy and effectiveness study results as they are reported for these and other vaccines.

A c c e p t e d M a n u s c r i p t M a n u s c r i p t Sensitivity assumed to be equal for symptomatic and asymptomatic infections. Points and error bars represent the mean and 2.5 and 97.5 percentiles from 1000 simulations. At 100% specificity, a slight bias is observed for the serology-estimated because estimates based on the CIR bias towards zero over time, particularly in high incidence settings [8] . = vaccine efficacy against infection, CIR = cumulative incidence ratio, IRR = incidence rate ratio. A c c e p t e d M a n u s c r i p t 

Interpreting estimates of coronavirus disease 2019 (COVID-19) vaccine efficacy and effectiveness to inform simulation studies of vaccine impact: a systematic review

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study

Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines

Understanding COVID-19 vaccine efficacy

Sensitivity, specificity, and vaccine efficacy

Analyzing Vaccine Trials in Epidemics with Mild and Asymptomatic Infection

Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies

Interpreting vaccine efficacy trial results for infection and transmission

Vaccine Efficacy at a Point in Time

Introduction and Examples. Design and Analysis of Vaccine Studies

Overview of Vaccine Effects and Study Designs. Design and Analysis of Vaccine Studies

The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

Comparison of 16 serological SARS-CoV-2 immunoassays in 16 clinical laboratories

Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections

Specificity and positive predictive value of SARS-CoV-2 nucleic acid amplification testing in a low-prevalence setting

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Health Care Personnel, First Responders, and Other Essential and Frontline Workers -Eight

Association of Age with Likelihood of Developing Symptoms and Critical Disease among Close Contacts Exposed to Patients with Confirmed SARS-CoV-2 Infection in Italy

Age-dependent effects in the transmission and control of COVID-19 epidemics

Symptom reporting in over 1 million people: community detection of COVID-19. medRxiv

Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom

SARS-CoV-2 Seroconversion and Viral Clearance in Patients Hospitalized with COVID-19: Viral Load Predicts Antibody Response

A c c e p t e d M a n u s c r i p t 18 A c c e p t e d M a n u s c r i p t 21